Amphista's AMX-883 Presented at ASH Meeting
Amphista Therapeutics will give an oral presentation on its lead candidate AMX-883 at the American Society of Hematology meeting in New Orleans.
Updated on Nov. 5, 2026 in Biotech
Amphista Therapeutics, a Cambridge biopharma company, has had AMX-883 accepted for oral presentation at the American Society of Hematology Annual Meeting, running December 12-15 in New Orleans. CEO Dr Louise Modis will present the data, and a second abstract on the BRAMLIE trial is due in the ASH Blood Supplement.
Why it matters
The data focus on degrading BRD9 with AMX-883 to restrict transcription factor programs that sustain leukemic stem cells in acute myeloid leukemia. The presentation offers an early look at a targeted protein degradation approach in a hard-to-treat blood cancer.
The evidence is an oral presentation of data from the open-label, multi-part, dose escalation and optimisation BRAMLIE trial, scheduled for December 12-15. The source does not provide efficacy figures, and the results have not yet been reported.
The players
Amphista Therapeutics
A biopharma company based in Granta Park, Cambridge, focused on non-cereblon and VHL targeted protein degradation medicines, originally spun out of the University of Dundee.
Dr Louise Modis
The chief executive of Amphista Therapeutics, who will present the AMX-883 data at the ASH meeting.
The details
AMX-883 is Amphista's lead candidate, a non-cereblon and VHL-targeted protein degradation medicine. The data suggest that BRD9 degradation maintains a block on differentiation and reduces the frequency of leukemic stem cells, a mechanism linked to hematopoietic transcription factors.
Timeline
December 12-15: American Society of Hematology Annual Meeting in New Orleans, where AMX-883 data will be presented
Field Context
AMX-883 extends targeted protein degradation beyond the cereblon-based drugs that dominated earlier development by using non-cereblon and VHL E3 ligase recruiters. Its focus on BRD9 in acute myeloid leukemia positions it as a test of that broader degrader strategy.
For patients with acute myeloid leukemia, a therapy that reduces leukemic stem cells could eventually change treatment options, though AMX-883 is still in clinical development. The presentation does not yet indicate when it may be available or how it would be accessed.
The takeaway
Targeted protein degradation is expanding beyond its first drug classes, and the December ASH presentation will show whether degrading BRD9 can meaningfully reduce leukemic stem cells. Readers tracking leukemia treatment should watch the conference data for clinical results.
What happens next
The ASH Annual Meeting presentation runs December 12-15 in New Orleans, and a second BRAMLIE trial abstract is due in the ASH Blood Supplement.
Further reading
For more on the field, see Biotech coverage of drug development and clinical research.
